Rating on Global Blood Therapeutics (GBT) Given is “Overweight”. Its Keeps by Cantor Fitzgerald with $96 Target.

June 29, 2018 - By Joshua Cleveland

Global Blood Therapeutics, Inc. (NASDAQ:GBT) Corporate Logo

Reiterated Global Blood Therapeutics (GBT) Rating.

Cantor Fitzgerald’s Stock analysts have $96 target price which gives upside potential of 107.79 % on Global Blood Therapeutics (GBT). a report of the firm was disclosed to clients on 28 June.

Global Blood Therapeutics, Inc. (NASDAQ:GBT) Ratings Coverage

A total of 10 analysts rate Global Blood Therapeutics (GBT) as follows: 9 “Buy”, 1 “Hold” and 0 “Sell”. Тherefore 90% are bullish. (GBT) has 25 ratings reports on Jun 29, 2018 according to StockzIntelligence. On Friday, June 15 the firm has “Buy” rating given by Cantor Fitzgerald. The stock rating was maintained by William Blair with “Buy” on Wednesday, February 28. On Wednesday, February 28 the firm has “Overweight” rating given by Cantor Fitzgerald. In Thursday, May 24 report H.C. Wainwright maintained the stock with “Buy” rating. On Wednesday, March 21 Morgan Stanley downgraded Global Blood Therapeutics, Inc. (NASDAQ:GBT) to “Equal-Weight” rating. On Monday, June 18 the firm has “Buy” rating given by Wedbush. The stock rating was maintained by Oppenheimer with “Buy” on Wednesday, February 28. The stock rating was maintained by Oppenheimer with “Buy” on Sunday, June 17. On Tuesday, May 8 the stock of Global Blood Therapeutics, Inc. (NASDAQ:GBT) earned “Buy” rating by SunTrust. On Monday, March 12 the stock of Global Blood Therapeutics, Inc. (NASDAQ:GBT) earned “Buy” rating by H.C. Wainwright.

Ticker’s shares touched $46.2 during the last trading session after 2.63% change.Global Blood Therapeutics, Inc. has volume of 756,397 shares. Since June 29, 2017 GBT has risen 60.31% and is uptrending. GBT outperformed the S&P 500 by 47.74%.

Global Blood Therapeutics, Inc. (NASDAQ:GBT)’s earnings release is anticipated by WallStreet on August, 6, Faxor reports. This year’s earnings per share analyst estimate is anticipated to be $-0.87. That is 58.18 % down compareed to $-0.55 earnings per share for last year. After $-0.87 EPS report previous quarter, Wall Street now sees 0.00 % EPS growth of Global Blood Therapeutics, Inc..

Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood disorders.The company has $2.39 billion market cap. The Company’s lead product candidate is voxelotor, an oral once-daily therapy that modulates hemoglobin's affinity for oxygen, which is in Phase III clinical trials in adult and adolescent patients with sickle cell disease .Currently it has negative earnings. The firm is also involved in evaluating the safety and pharmacokinetics of single and multiple doses of voxelotor in a Phase IIa clinical trials of adolescent and pediatric patients with SCD; and other research and development activities that are in pre-clinical phase.

For more Global Blood Therapeutics, Inc. (NASDAQ:GBT) news published briefly go to: Nasdaq.com, Fool.com, Benzinga.com, Streetinsider.com or Seekingalpha.com. The titles are as follows: “GBT Announces Positive Top-line Data from Part A of the Phase 3 HOPE Study of Voxelotor in Sickle Cell Disease” published on June 27, 2018, “Why Sangamo Therapeutics and bluebird bio Slipped Lower Today” on June 27, 2018, “Global Blood Therapeutics Meets Primary Endpoints In Sickle Cell Study, Seeks Accelerated FDA Approval” with a publish date: June 27, 2018, “Global Blood Therapeutics (GBT) Reports Statistically Significant Results from Part A of the Phase 3 HOPE Study of …” and the last “GBT’s voxelotor shows lower treatment effect in adolescents with SCD in mid-stage study; shares slip 4% premarket” with publication date: June 15, 2018.

Global Blood Therapeutics, Inc. (NASDAQ:GBT) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.